CoChat

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series

Open access

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index; 11 of the 27 sources its claims cite were checked for support.

Abstract

Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary evidence supporting efficacy in AAWG. Semaglutide is a weekly injectable GLP-1RA which received recent approval for obesity management and noted superiority over other GLP-1RAs. This study explored the efficacy and tolerability of semaglutide in AAWG among individuals with severe mental illness. A retrospective chart review of patients treated with semaglutide in the Metabolic Clinic at the Center for Addiction and Mental Health (CAMH) between 2019 and 2021 was conducted. Patients failing a trial of metformin (<5% weight loss or continuing to meet criteria for metabolic syndrome) after 3 months at the maximum tolerated dose (1500–2000 mg/day) were initiated on semaglutide up to 2 mg/week. The primary outcome measure was a change in weight at 3, 6, and 12 months. Twelve patients on weekly semaglutide injections of 0.71 ± 0.47 mg/week were included in the analysis. About 50% were female; the average age was 36.09 ± 13.32 years. At baseline, mean weight was 111.4 ± 31.7 kg, BMI was 36.7 ± 8.2 kg/m 2 , with a mean waist circumference of 118.1 ± 19.3 cm. A weight loss of 4.56 ± 3.15 kg ( p < 0.001), 5.16 ± 6.27 kg ( p = 0.04) and 8.67 ± 9 kg ( p = 0.04) was seen at 3, 6, and 12 months, respectively, after initiation of semaglutide with relatively well-tolerated side-effects. Initial evidence from our real-world clinical setting suggests that semaglutide may be effective in reducing AAWG in patients not responding to metformin. Randomized control trials investigating semaglutide for AAWG are needed to corroborate these findings.

Overview

CoChat Summary

## TL;DR

This retrospective case series evaluated semaglutide for antipsychotic-associated weight gain in 12 patients who had not responded to metformin. Weight loss was observed at 3, 6, and 12 months, with relatively well-tolerated mostly gastrointestinal side effects.

## Key findings

  • From 399 patients seen in the clinic between March 2019 and May 2021, 12 patients (3%) met inclusion criteria and were analyzed.
  • Mean weight loss after semaglutide was 4.56 ± 3.15 kg at 3 months (p < 0.001), 5.16 ± 6.27 kg at 6 months (p = 0.04), and 8.67 ± 9 kg at 12 months (p = 0.04).
  • This corresponded to average weight loss of 5% at 3 months, 6.6% at 6 months, and 8.7% at 12 months; 50% of patients lost more than 5%, and 41.6% lost more than 7% of baseline weight.
  • Four patients (33%) reported gastrointestinal side effects (nausea, vomiting, diarrhea), which decreased over time; no serious adverse events were reported.

## Methods

  • Retrospective chart review of patients attending the Mental health and Metabolism clinic at CAMH, Toronto, between March 2019 and May 2021.
  • Included patients had stable antipsychotic treatment (>3 months), met criteria for adjunctive pharmacological intervention, and had failed metformin defined as <5% weight loss in 3 months or persistent metabolic syndrome after 3 months.
  • Baseline and follow-up data at 3, 6, and 12 months were extracted; outcomes were analyzed with descriptive statistics, t-tests/chi-square, and a mixed-model analysis of time on weight.

## Limitations

  • The paper states the study was a small convenience sample and a case series.
  • The paper states semaglutide doses were well below the approved obesity dose (mean 0.7 mg weekly vs 2.4 mg weekly), because data were collected before the higher-dose obesity approval.
  • The paper states there was no placebo arm and treatment was open-label; it also states COVID-19 constraints limited follow-up and reduced available anthropometric and laboratory data.
  • Evident from the text: the sample was small (12 patients) and some follow-up data were missing at later time points (10 patients at 6 months, 8 at 12 months), which limits generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/20451253231165169

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Line graphs depicting change in body weight over time of the overall cohort and individual patients.
Figure 1. Line graphs depicting change in body weight over time of the overall cohort and individual patients.CC BY-NC · PubMed Central
Figure 2. Percentage change in body weight from baseline of patients included in the study.
Figure 2. Percentage change in body weight from baseline of patients included in the study.CC BY-NC · PubMed Central

Verification

Claims the paper makes

4 Valid · 2 Not valid · 3 Not checked · 21 Own results and interpretations

14 more claims

Create a free account to see all 30 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 6
  • It may state two separate claims as one. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Research works printed but not linked: 1

  1. Patino LR, 2015, Biol Psychiatry, 77

Cited by

See all 88

Metadata

Authors
Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., Hahn, M. K., & Agarwal, S. M.
Affiliations
  • Centre for Addiction and Mental Health (CA)
  • University of Copenhagen (DK)
  • The University of Queensland (AU)
  • Center for Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark
Corresponding author
Agarwal, Sri Mahavir
Venue
Therapeutic Advances in Psychopharmacology
Published
2023-01
Volume
13
Pages
20451253231165169-20451253231165169
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W4366433723
Cited by
88
References
53
Citations by year
2026: 14 · 2025: 51 · 2024: 18 · 2023: 5
FWCI
13.66
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Steno Diabetes Center Copenhagen (SDCC 3.F CMP)
  • Physicians' Services Incorporated Foundation
  • University of Toronto
  • HLS Therapeutics
  • Department of Psychiatry, University of Toronto
  • Canadian Institutes of Health Research
  • Banting and Best Diabetes Centre, University of Toronto
  • National Health and Medical Research Council (1194635)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
semaglutide, GLP-1 receptor agonists, severe mental illness, weight loss, obesity treatment, metabolic syndrome, tolerability, real-world effectiveness, treatment-resistant obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series. https://app.cochat.ai/papers/10.1177/20451253231165169
The paper
Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., Hahn, M. K., & Agarwal, S. M. (2023). Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253231165169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.